Number of the records: 1
Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009-2014)
- 1.
SYSNO ASEP 0448652 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Článek ve WOS Title Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009-2014) Author(s) Malínková, Veronika (UEB-Q) ORCID, RID
Vylíčil, Jakub (UEB-Q)
Kryštof, Vladimír (UEB-Q) RID, ORCIDSource Title Expert Opinion on Therapeutic Patents - ISSN 1354-3776
Roč. 25, č. 9 (2015), s. 953-970Number of pages 18 s. Language eng - English Country GB - United Kingdom Keywords cancer ; CDK ; cyclin Subject RIV EB - Genetics ; Molecular Biology R&D Projects LO1204 GA MŠMT - Ministry of Education, Youth and Sports (MEYS) ED3.1.00/14.0327 GA MŠMT - Ministry of Education, Youth and Sports (MEYS) GA15-15264S GA ČR - Czech Science Foundation (CSF) Institutional support UEB-Q - RVO:61389030 UT WOS 000361269100002 DOI 10.1517/13543776.2015.1045414 Annotation Introduction: Cell cycle deregulation is a common characteristic of cancer cells. Progression through the cell cycle is controlled by enzymes known as cyclin-dependent kinases (CDKs), whose activity can be upregulated by a wide range of molecular mechanisms. Based on these observations, small molecule CDK inhibitors are being developed as potential cancer therapeutics. Some of these compounds have entered Phase Ill clinical trials and one of them, palbociclib, recently received accelerated approval from the FDA. However, the complexity of CDK biology and the undesired side effects of the existing inhibitors mean that the hunt for new CDK-targeting drug candidates continues. Areas covered: This article reviews patent applications related to small molecule CDK inhibitors published between 2009 and 2014. Expert opinion: Clinical trials with pan-specific inhibitors have generally yielded unambiguously positive outcomes. However, better results have been achieved with highly specific inhibitors of CDK4/CDK6. This may be due to several factors and has generated considerable interest in the discovery of new mono-specific CDK inhibitors. The development of such compounds is challenging because all CDKs have very similar active sites. Aside from this issue of selectivity, another key challenge is the identification of patients who will benefit from specific therapies. Workplace Institute of Experimental Botany Contact David Klier, knihovna@ueb.cas.cz, Tel.: 220 390 469 Year of Publishing 2016
Number of the records: 1